MaxCyte shares gain 5% on raised full-year revenue guidance
Commercial cell-engineering company MaxCyte (MXCT:AIM) increased full-year revenue guidance on Tuesday after reporting a strong first quarter to 31 March 2022.Based on expectations for the core business which generates revenue from instrument and disposables sales to cell therapy and drug discovery customers, management anticipates 'at least' 25% growth for the full year.The company also reiterate